Targeting delivery in Parkinson's disease.
Disease-modifying therapies for Parkinson's disease (PD), with the potential to halt the neurodegenerative process and to stimulate the protection, repair, and regeneration of dopaminergic neurons, remain a vital but unmet clinical need. Targeting the delivery of current and new therapeutics directly to the diseased brain region (in particular the nigrostriatal pathway) could result in greater improvements in the motor functions that characterise PD. Here, we highlight some of the opportunities and challenges facing the development of the next generation of therapies for patients with PD.
Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, UK; Leibniz-Institut für Polymerforschung, Dresden, Germany.
Ben
B
Newland
Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, UK.
Stephen B
SB
Dunnett
Pharmacology & Therapeutics, National University of Ireland, Galway, Ireland. Electronic address: eilis.dowd@nuigalway.ie.
Eilís
E
Dowd
D000818:Animals; D064987:Cell- and Tissue-Based Therapy; D016503:Drug Delivery Systems; D006801:Humans; D018696:Neuroprotective Agents / Q000008:administration & dosage; D010300:Parkinson Disease / Q000628:therapy*; D013238:Stereotaxic Techniques
D018696:Neuroprotective Agents